LABCORP HOLDINGS INC
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Index
Item 2. PROPERTIES
The Company’s corporate headquarters are located in Burlington, North Carolina, and include facilities that are both owned and leased.
Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The table below summarizes certain information as to Dx’s principal operating and administrative facilities at December 31, 2024.
| Location | Nature of Occupancy |
|---|---|
| Primary Facilities: | |
| Birmingham, Alabama | Leased |
| Phoenix, Arizona | Owned |
| Los Angeles, California | Leased |
| Monrovia, California | Leased |
| San Diego, California | Leased |
| San Francisco, California (2) | Leased |
| Shelton, Connecticut | Leased |
| Tampa, Florida | Leased |
| South Bend, Indiana | Leased |
| Wichita, Kansas | Leased |
| Baltimore, Maryland | Leased |
| Holyoke, Massachusetts | Leased |
| Westborough, Massachusetts | Leased |
| Troy, Michigan | Leased |
| St. Paul, Minnesota | Owned |
| Raritan, New Jersey | Owned |
| Burlington, North Carolina (5) | Owned/Leased |
| Research Triangle Park, North Carolina (3) | Leased |
| Dublin, Ohio | Owned |
| Tulsa, Oklahoma | Leased |
| Brentwood, Tennessee | Leased |
| Dallas, Texas | Leased |
| Houston, Texas | Leased |
| Herndon, Virginia | Leased |
| Seattle, Washington | Leased |
| Spokane, Washington (2) | Leased |
| Oak Creek, Wisconsin | Leased |
Index
BLS operates on a global scale. The table below summarizes certain information as to BLS’s principal operating and administrative facilities at December 31, 2024.
| Location | Nature of Occupancy |
|---|---|
| Primary Facilities: | |
| Mechelen, Belgium | Leased |
| Shanghai, China (2) | Leased/Owned |
| Muenster, Germany | Owned |
| Bangalore, India | Leased |
| Kawagoe, Japan | Leased |
| Singapore | Leased |
| Geneva, Switzerland (2) | Owned/Leased |
| Eye, United Kingdom | Owned |
| Harrogate, United Kingdom | Owned |
| Huntingdon, United Kingdom | Owned |
| Shardlow, United Kingdom | Owned |
| York, United Kingdom | Leased |
| Los Angeles, California | Leased |
| Greenfield, Indiana | Owned |
| Indianapolis, Indiana | Leased |
| Bedford, Massachusetts | Owned |
| Ann Arbor, Michigan | Leased |
| Somerset, New Jersey | Owned |
| Denver, Pennsylvania | Leased |
| Brentwood, Tennessee | Leased |
| Chantilly, Virginia | Leased |
| Madison, Wisconsin | Owned |
All of the Company’s primary facilities have been built or improved for the purpose of providing commercial laboratory testing or biopharma laboratory services. The Company believes that these existing facilities and plans for expansion are suitable and adequate and will provide sufficient production capacity for the Company’s currently foreseeable level of operations. The Company believes that if it were unable to renew a lease or if a lease were to be terminated on any of the facilities it presently leases, it could find alternate space at competitive market rates and readily relocate its operations to such new locations without material disruption to its operations.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.